PDXNet

The National Cancer Institute (NCI) launched the PDX (patient-derived xenografts) Development and Trial Centers Research Network (PDXNet) in September 2017 to accelerate translational research using PDX datasets. The NCI renewed the program in 2023 with a focus of generating new LOIs.

The PDXNet comprises six PDX Development and Trial Centers (PDTCs) and the PDX Data Commons and Coordinating Center (PDCCC). PDXNet also works closely with the NCI Patient-Derived Model Repository (PDMR) to ensure data are collected and provided in a standardized format. Collectively, the PDTCs and the PDCCC work together to test and advance multi-agent cancer treatments from PDX studies to human clinical trials.

PDXNet is an inclusive consortium welcoming collaborations. Please contact us to discuss how we can work together to advance new cancer treatments.

Please visit the PDXNet portal to review resources generated by the PDXNet community.

 

520 Novel Models Developed

Number of PDX Models by Body Location

Funding is provided by the NIH to the PDXNet Data Commons and Coordination Center (NCI U24-CA224067), and to the PDX Development and Trial Centers (NCI U54-CA224076, NCI U54-CA224083, NCI U54-CA224070, NCI U54-CA283759, NCI U54-CA283766, and U54-CA283762)